A Bayesian network meta-analysis: evaluating the efficacy and safety of targeted therapies in metastatic or advanced radioiodine-refractory differentiated thyroid cancer.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
760 patients with RAIR-DTC.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The time-dependent efficacy patterns of other TKIs warrant further investigation. [SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420251089713, identifier CRD420251089713.
[BACKGROUND] Approximately 5%-10% of patients with differentiated thyroid cancer (DTC) develop resistance to radioactive iodine (RAI), leading to unsatisfactory survival rates.
- OR 143.18
- 연구 설계 meta-analysis
APA
Wang P, Li L, et al. (2026). A Bayesian network meta-analysis: evaluating the efficacy and safety of targeted therapies in metastatic or advanced radioiodine-refractory differentiated thyroid cancer.. Frontiers in oncology, 16, 1720670. https://doi.org/10.3389/fonc.2026.1720670
MLA
Wang P, et al.. "A Bayesian network meta-analysis: evaluating the efficacy and safety of targeted therapies in metastatic or advanced radioiodine-refractory differentiated thyroid cancer.." Frontiers in oncology, vol. 16, 2026, pp. 1720670.
PMID
41836236 ↗
Abstract 한글 요약
[BACKGROUND] Approximately 5%-10% of patients with differentiated thyroid cancer (DTC) develop resistance to radioactive iodine (RAI), leading to unsatisfactory survival rates. The optimal medication for advanced or metastatic RAI-resistant differentiated thyroid cancer (RAIR-DTC) remains unclear.
[METHODS] We conducted a Bayesian network meta-analysis based on a systematic search of six electronic databases. The primary outcome was progression-free survival (PFS); secondary outcomes included overall survival (OS), objective response rate (ORR), and grade ≥3 adverse events (AEs). Hazard ratios (HRs) with 95% credible intervals (CrIs) were used for time-to-event outcomes, while odds ratios (ORs) with 95% CrIs were used for binary outcomes. A separate Bayesian network meta-analysis was performed for each endpoint.
[RESULTS] Our study included 9 RCTs involving 1,760 patients with RAIR-DTC. Lenvatinib, anlotinib, apatinib, and cabozantinib all significantly improved PFS versus placebo (HRs: 3.85-5.36), with lenvatinib ranking first overall (SUCRA: 81.97%) and showing sustained benefit up to 24 months. Apatinib provided early PFS advantage but waning efficacy beyond 6-9 months. No treatment significantly improved OS, though apatinib consistently ranked highest for OS. Lenvatinib achieved the highest objective response rate (OR = 143.18; SUCRA: 82.09%). For grade ≥3 adverse events, no treatment differed significantly from placebo; however, apatinib ranked highest in safety (SUCRA = 93.16%).
[CONCLUSION] Lenvatinib demonstrates the greatest benefit in both PFS and ORR among the evaluated TKIs for RAIR-DTC, suggesting it as a potential preferred first-line option. The time-dependent efficacy patterns of other TKIs warrant further investigation.
[SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420251089713, identifier CRD420251089713.
[METHODS] We conducted a Bayesian network meta-analysis based on a systematic search of six electronic databases. The primary outcome was progression-free survival (PFS); secondary outcomes included overall survival (OS), objective response rate (ORR), and grade ≥3 adverse events (AEs). Hazard ratios (HRs) with 95% credible intervals (CrIs) were used for time-to-event outcomes, while odds ratios (ORs) with 95% CrIs were used for binary outcomes. A separate Bayesian network meta-analysis was performed for each endpoint.
[RESULTS] Our study included 9 RCTs involving 1,760 patients with RAIR-DTC. Lenvatinib, anlotinib, apatinib, and cabozantinib all significantly improved PFS versus placebo (HRs: 3.85-5.36), with lenvatinib ranking first overall (SUCRA: 81.97%) and showing sustained benefit up to 24 months. Apatinib provided early PFS advantage but waning efficacy beyond 6-9 months. No treatment significantly improved OS, though apatinib consistently ranked highest for OS. Lenvatinib achieved the highest objective response rate (OR = 143.18; SUCRA: 82.09%). For grade ≥3 adverse events, no treatment differed significantly from placebo; however, apatinib ranked highest in safety (SUCRA = 93.16%).
[CONCLUSION] Lenvatinib demonstrates the greatest benefit in both PFS and ORR among the evaluated TKIs for RAIR-DTC, suggesting it as a potential preferred first-line option. The time-dependent efficacy patterns of other TKIs warrant further investigation.
[SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420251089713, identifier CRD420251089713.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Application progress of tRNA modification in gynecological tumors: A review.
- Integrated analysis and functional validation reveal KCNQ1 tumor suppressor targeting by dahuang Zhechong Pills via cuproptosis modulation in colorectal cancer.
- siRNA Nanoparticle Delivery Strategies and Clinical Trial Advances in Tumor Therapy.
- Retraction notice to "A chitosan-camouflaged nanomedicine triggered by hierarchically stimuli to release drug for multimodal imaging-guided chemotherapy of breast cancer" [Carbohydrate Polymers 335 (2024) 122073].
- Succinylated D-Type Neuropeptide Integrated with Iron-Based Probes for Regulating Mitochondrial Function and Homeostasis in Breast Cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Evaluating Clinical Efficacy and Survival Outcomes of Crizotinib in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis.
- Prognostic Value of Baseline Systemic Immune-Inflammation Index in Advanced Intrahepatic Cholangiocarcinoma Treated with First-Line Gemcitabine-Cisplatin Plus PD-L1 Inhibitor: A Single-Center Retrospective Study.
- Predictive value of the systemic immune-inflammation index and geriatric nutritional risk index on the efficacy of immunotherapy and survival prognosis in advanced non-small cell lung cancer: a retrospective study.
- PD-L1 status on circulating tumor cells: a promising predictor in advanced lung cancer with PD-1/PD-L1 immunotherapies.
- Comparative effectiveness and safety of second-line therapies and dosing regimens for advanced hepatocellular carcinoma: a network meta-analysis.
- Efficacy and safety of immune checkpoint inhibitors combined with chemoradiotherapy in locally advanced cervical cancer: a systematic review and meta-analysis.